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Abstract  
Traumatic Brain Injury (TBI) frequently triggers a disruption of cerebral autoregulation. The cerebral 
perfusion pressure (CPP) at which autoregulation is optimal (“CPPopt”) varies between individuals, 
and can be calculated based on fluctuations between arterial blood pressure and intracranial 
pressure. This review assesses the effect of individualising cerebral perfusion pressure targets to 
pressure reactivity index (a measure of autoregulation) in patients with TBI.  
 
Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and Cumulative Index of Nursing 
and Allied Health Literature were searched in March 2015 for studies assessing the effect of 
targeting CPPopt in TBI. We included all studies which assessed the impact of targeting CPPopt on 
outcomes including mortality, neurological outcome and physiological changes. Risk of bias was 
assessed using the RTI Item Bank and evidence quality considered using the GRADE criteria.  
 
Eight cohort studies (based on six distinct datasets) assessing the association between CPPopt and 
mortality, Glasgow Outcome Scale and physiological measures in TBI were included. The quality of 
evidence was deemed very low based on the GRADE criteria. Whilst the data suggests an association 
between variation from CPPopt and poor clinical outcome at 6 months, the quality of evidence 
prevents firm conclusions, particularly regarding causality, being drawn.  
 
Available data suggests that targeting CPPopt might represent a technique to improve outcomes 
following TBI, but currently there is insufficient high-quality data to support a recommendation for 
use in clinical practice. Further prospective, randomised controlled studies should be undertaken to 
clarify its role in the acute management of TBI.  
 
Keywords: Traumatic Brain Injury, CBF Autoregulation, Vascular Reactivity, Therapeutic Approaches 
for the treatment of CNS injury 
Introduction 
Traumatic brain injury (TBI) is the leading cause of death and disability in young adults, with a 
significant personal, social and economic impact. In Europe alone, around 2.5 million people will 
sustain a TBI per year, of which 1 million will be admitted to hospital. Despite improvements in care, 
75,000 of these will die, and a substantial proportion of survivors will suffer ongoing disability.1 
Following TBI, maintenance of appropriate cerebral blood flow is imperative to mitigate against the 
relative adverse effects of ischaemia and hyperaemia. In healthy states, the cerebral vasculature 
compensates for variations in systemic blood pressure and cerebral metabolic requirements with 
judicious alterations of blood vessel diameter, known as autoregulation.2 In injured brains, this 
autoregulation can be impaired, and observational studies have demonstrated a relationship 
between loss of autoregulation and poor outcome.3-6 
In patients with poor intracranial compliance, changes in cerebral blood volume, as dictated by 
vessel diameter, are expressed as variations in intracranial pressure (ICP). By analysing the dynamic 
relationship between mean arterial pressure (MAP) and ICP over a given time period (the length may 
be chosen arbitrary, but it should be substantially longer than respiratory and pulse period), an 
appreciation of cerebrovascular pressure reactivity can be gained, providing information about the 
integrity of autoregulation.7 Perhaps the best known calculated index of cerebral autoregulation in 
the Pressure Reactivity Index (PRx), which is correlation coefficient between ICP and arterial 
pressure using ten seconds-averaged samples as datapoints and calculating correlation coefficients 
using a 5 min data window. 
Measurement of PRx allows an assessment of the effect of various therapeutic manoeuvres on 
autoregulation. Changes in cerebral perfusion pressure (CPP),8 temperature9 and respiration10 
modulate autoregulation, as does the use of certain anaesthetic agents.11,12 
Investigation into the effect of CPP on autoregulation has led to the discovery that the CPP at which 
autoregulation is best preserved (“optimal CPP” or CPPopt) varies both between individuals, and 
throughout time in an individual patient.13 Certain neurocritical care units utilise CPPopt techniques 
as an adjunct to standard care, in order to tailor CPP targets to each patient. To date, however, there 
are no systematic reviews assessing its clinical utility.  
The objective of this systematic review is to determine the effect of individualising CPP targets to 
optimal PRx compared with standard CPP targets in patients with moderate to severe TBI on 
mortality and functional recovery. 
 
Materials and methods 
This review was conducted and reported in line with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) Statement.14 Details of the protocol for this systematic review 
were registered on PROSPERO (registration number CRD42014013048) and can be accessed at 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014013048#.VWQ7K0Z0eSo. 
 
The review is being prepared as part of the CENTER-TBI project, a large European research project 
that aims to improve the care for patients with Traumatic Brain Injury. 1,15,16  
 
Information sources 
Using the NHS Library Healthcare Database search engine, the following databases were searched up 
to March 2015: Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and Cumulative 
Index of Nursing and Allied Health Literature. There were no language or date restrictions, and we 
included studies irrespective of publication status. The search strategy was developed in 
consultation with a search expert using the following combination of subject headings and 
keywords: (Brain Injuries/ or Craniocerebral Trauma/ or ((head* or brain*) adj2 (injur* or 
trauma*)).ti,ab)17 AND (Cerebral perfusion pressure OR Pressure reactivity OR Cerebrovascular 
reactivity.ti,ab ). 
Grey literature, ongoing trials and conference abstracts were searched for via The ClinicalTrials.gov 
registry, Google Scholar and abstracts from neurocritical care and international neurotrauma 
conferences. Reference lists from included studies and other pertinent articles were screened, and 
citation tracking of included studies (via SCOPUS) was conducted. Experts leading research into 
cerebrovascular reactivity were consulted to identify any unpublished data. 
 
Study selection 
We included RCTs, quasi-RCTs, CCTs, and observational studies with a control group (i.e. cohort 
studies and case-control studies) that investigated the effect of targeting CPPopt in patients with 
moderate to severe TBI on one or more of our relevant outcomes. These outcomes included: 
mortality, functional outcomes (e.g. Glasgow Outcome Scale (GOS)) and physiological measures 
(such as brain tissue oximetry).  Whilst we recognise the limitations of including observational 
studies in a systematic review of intervention effectiveness, an anticipated lack of controlled trials 
necessitated this decision in order to comprehensively evaluate the available data. We included all 
age groups and any methods for calculating CPPopt.  Studies not measuring any of our pre-specified 
outcomes were excluded. 
The first author (EN) screened all search results on citation, and removed clearly irrelevant articles. 
Two authors (EN, VN) then independently screened the remaining citations and abstracts identified 
to determine their eligibility for inclusion. Agreed citations were retrieved in full text and reviewed 
by the two authors independently; any disagreement was resolved by discussion until consensus was 
reached. 
 
Data collection and assessment of risk of bias 
Two authors (EN, CM) independently assessed the risk of bias of included studies; disagreement was 
resolved by discussion until consensus was reached. Data extraction was conducted by EN and 
corroborated by CM. The following data was extracted from the studies: study characteristics 
(including site and year), study participants (e.g. number, age, severity), method for calculating 
CPPopt, and clinical outcomes.  
Where dichotomous data was available, we presented it as risk ratios (RR) with p-values. Continuous 
data was presented in the form that it appeared in the original publication. 
Risk of bias was assessed using the RTI item bank.18 The RTI item bank assesses risk of bias based on 
12 domains. Each domain is rated as low, high or unclear risk of bias, according to specific criteria.  
 
 
Data synthesis 
To synthesise the data, we grouped studies by outcome, and considered the results of each study 
contributing to that outcome. Due to the heterogeneity of design and outcome measures, we report 
the results in a narrative manner, rather than performing meta-analysis. Where studies used shared, 
or overlapping datasets, this is highlighted. The risk of bias of included studies was used to inform an 
assessment of the quality of the evidence contributing to each outcome, as per the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) approach.19 According to the 
GRADE approach, observational research is considered to be low quality evidence that may be 
downgraded further (or in rare instances upgraded) according to specific criteria. 
Two authors (EN,AS) independently applied the GRADE criteria for each outcome and reached 
agreement through discussion (Supplementary Table 1). 
 
Results 
Study selection 
A total of 2022 de-duplicated citations were identified, with 74 titles included on citation and 
abstract, and 22 retrieved in full text. Of these, 12 studies did not address the relationship between 
CPPopt and a clinically relevant outcome, and two abstracts20,21 reported the same data as full text 
reports22,23 thus were also excluded (Supplementary Table 2). Of the eight included studies, six were 
full texts, and two were abstracts from conference proceedings (Figure 1). There were no 
disagreements between the authors. 
 Study characteristics 
We included eight study reports, assessing the effect of CPPopt in 972 patients with moderate to 
severe TBI (Table 1). One study group (Cambridge, UK) published three articles using overlapping, 
but not identical, datasets.22,24,25 Due to overlap of patients in these three studies, we collated them 
as the “Cambridge Cohort”. Therefore, there were six entirely distinct datasets. All studies took place 
in academic neuroscience centres in high-income countries. No studies assessed the use of CPPopt in 
children. All studies used a cohort design, with six studies retrospectively analysing prospectively 
gathered observational data.22-26,28 The remaining two were prospective studies; one assessed the 
feasibility of adhering to a CPPopt-guided protocol,29 and the other assessed the effects of targeting 
CPPopt on the partial pressure of brain tissue oxygen (PbrO2).27 No study directly compared a 
CPPopt-guided protocol with standard CPP targets.  
Seven of the studies produced CPPopt data using ICM+ software, which analyses high-frequency 
ICP/CPP data to calculate an optimal individualised CPP target, based on the PRx values seen over a 
range of CPP levels. (http://www.neurosurg.cam.ac.uk/pages/ICM/).22-25, 27-29 Two of these also used 
alternative methods: dynamic adaptive target of active cerebral autoregulation (DATCAR), a 
technique using the weighted averages of a number of low-resolution autoregulation index (LAx – a 
similar method to ICM+, but using low frequency data) curves generated at multiple time intervals 
and over multiple time windows,23 and Long-PRx (L-PRx), a PRx variant based on lower frequency 
changes in ICP/MAP.25 The remaining study used a bespoke technique which is not fully described.26 
These alternative methods are detailed further in Appendix 1. 
Six studies reported outcome data for mortality at six months,22-26,28 five GOS at six months,22,24,25,28,29 
one functional outcome (assessment tool not detailed) at six months 26 and one PbrO2.27  
All studies were funded by non-government sources. Five studies were co-authored by the creators 
of ICM+ software, who have a financial interest in a part of the licensing fee.22,24,25,28,29 
 
 Risk of bias 
Given the inherent paucity of data presented in abstract-only publications, these were considered to 
be at unclear risk of bias.24,26 Broadly, the remaining studies were judged as being at high risk of bias 
(Table 2). The main source of bias arose because of a failure to account for confounding factors in 
the analysis, such as intercurrent sepsis and severity of injury.22,25,28,29  One study performed 
multivariate analysis, thus addressing this to some degree,23 and one described physiological data 
only, therefore these were deemed at low risk.27 All data gathered were observational, and thus was 
only able to describe associations rather than apportion causality. 
 
Mortality 
All six studies assessing mortality reported an increased risk with variance from CPPopt, particularly 
when managed below CPPopt.22-26,28 This was displayed in differing ways across the studies: Aries 
(Cambridge cohort)22 and Colton26 described reduced mortality rates in those managed within 
5mmHg of CPPopt (RR 0.28, p = 0.01522 and RR 0.42 , p = not recorded (NR)26); Lang and Smielewski 
(Cambridge Cohort) and Steiner reported a decrease in mortality in those managed above CPPopt 
(no effect size stated, p <0.01;24,25RR 0.17, p = NR28); and Depreiterre showed that survivors spent 
longer within 5mmHg of CPPopt than non-survivors (25.6% vs 19.6% p = 0.01).23 The difference 
between actual CPP and CPPopt was an independent predictor of survival when using the CRASH 
outcome prediction model variables of age, Glasgow Coma Scale, pupil reactivity, and presence of 
extracranial injury as covariates for a multivariate logistic regression (p = 0.017).23 Lang also reported 
that 72% of non-survivors were managed with CPP lower than CPPopt (p = NR).25 
According to the GRADE criteria however, the quality of this evidence was judged as very low 
(downgraded for a failure to address potential confounding factors across most studies, and a lack of 
comparison to standard management), thus our confidence in effect estimate is limited, and firm 
conclusions of the effect of CPPopt on mortality cannot be drawn. 
 Neurological outcome 
All six studies assessing neurological outcome identified worsening in neurological outcome with 
variance from CPPopt, particularly when managed above CPPopt.22,24-26, 28,29 It should be noted that 
the commonly used definition of “poor outcome” (GOS 1 to3) incorporates death, and thus some of 
the following results composite disability and death.  
In Aries (Cambridge cohort), a good outcome (GOS 4 to5) at 6 months was more frequent in those 
with median CPP within 5mmHg of CPPopt; (RR 1.65, p ≤ 0.001). Severe disability (GOS 3) was 
particularly likely in patients with median CPP greater than 5mmHg above CPPopt (RR 1.88, p ≤ 
0.001).22 This pattern was reflected in Colton where risk of poor neurological outcome was higher in 
those with median CPP greater than 10mmHg away from CPPopt (RR 2.14, p = NR).26 As the 
neurological outcome scale used is not specified, the findings cannot be directly compared to Aries.22 
Lang and Smielewski (Cambridge cohort) found that CPP above CPPopt was associated with 
increased disability in their dataset, but did not publish the effect size (p = 0.005,25 p ≤0.02528). 
Conversely, Dias found that patients with poor outcome (GOS 3 or less) were managed with CPP 
lower than CPPopt (-6.6mmHg vs. -1.0mmHg, p = 0.004).29 Note here the inclusion of GOS 1 (Dead); 
the authors did not specify the proportion in the poor outcome group who died. 
Lastly, Steiner reports that the correlation between the difference of mean CPP and CPPopt 
(meanCPP-CPPopt) with GOS was highly significant (r= -0.51, p < 0.001), showing that the further 
from CPPopt a patient was managed, the worse the outcome. This correlation existed for those 
patients managed below CPPopt (r = 0.53, p < 0.001) and for those above CPPopt (r = -0.40, p ≤ 
0.05).28Again it should be noted that GOS of one was included here, and that the overall picture was 
of increased mortality below CPPopt, and increased disability above it.  
The pattern described in these studies suggests that the CPPopt is the point at which CPP is high 
enough to maximise likelihood of survival, whilst minimising the detrimental effects of cerebral 
hyperaemia. 
We judged the quality of this evidence to be very low (downgraded again for a failure to address 
potential confounding factors across most studies, and a lack of comparison to standard 
management), and therefore firm conclusions cannot be drawn. 
 
Physiological outcomes:  
One study assessed the relationship between CPPopt and a physiological outcome. Jaeger found a 
significant correlation between CPPopt and the PbrO2 change point (CPPPbrO2), the level at which 
PbrO2 no longer rises in a pressure-passive manner alongside CPP (r = 0.79, p < 0.001). Up to and 
including CPPopt, the CPP and PbrO2 correlated (r = 0.51, p < 0.001), whereas no such correlation 
existed above CPPopt (r = 0.03, p = 0.67), displaying that brain oxygenation improved up to the point 
of CPPopt, but no further.27 
Once more the quality of this evidence was rated as very low (downgraded as the physiological 
changes represent only a surrogate for clinical outcome, and sample size was very small), and so firm 
conclusions cannot be drawn. 
 
Discussion 
We found eight studies, based on six distinct datasets, assessing the effect of optimising CPP targets 
to PRx. Six of these addressed mortality risk,22-26,28  six disability22,24-26, 28,29 and one PbrO2.27 Six 
studies were retrospective observational trials,22-26,28 whilst the remaining two were undertaken 
prospectively.27,29 
All studies which assessed neurological outcome suggested an association between proximity of 
actual CPP to CPPopt and improved outcome.22-6, 28-29   One centre reported a pattern of increased 
mortality when actual CPP was lower than CPPopt, and increased disability when above it.22,24,25,28 
One study displayed an association between CPPopt and the point at which increases in CPP cease to 
improve brain tissue oxygenation.27 
However, owing to the very low quality of the evidence (predominantly through a failure to address 
the impact of confounding factors which might associate variance from CPPopt and the measured 
outcomes e.g. shock, and a lack of comparison to standard practice), the results must be interpreted 
with caution. The nature of very low quality evidence is such that future, robust experimental 
studies may strengthen but, equally, may contradict these findings. As such, we are unable to draw 
any firm conclusions about the effect of optimising CPP targets to PRx on any outcomes. 
Additionally, targeting PbrO2 thresholds have not been unequivocally shown to improve clinical 
outcomes, and therefore extrapolating the association between CPPopt and CPPPbrO2 to infer a 
clinically significant effect is as yet unjustified. The other outcomes measures investigated however, 
are well validated and clinically relevant. 
Overall, there is an absence of prospective, controlled trials addressing the utility of targeting 
CPPopt. In this review, all studies were observational, and described associations based on variance 
from CPPopt, rather than comparing a CPPopt-based strategy to usual practice. They could therefore 
only hope to demonstrate association rather than causality; confounding factors, such as shock, 
could well create such an association between poor outcome and variance from CPPopt, and were 
not sufficiently accounted for. However, the risk that this confound was a major cause of the 
observed association with outcome is mitigated by the finding of poorer outcomes when CPP was 
greater than CPPopt. 
To the best of our knowledge, this is the first systematic review published on this topic. Most 
evidence up to this point has addressed the effect of targeting universal CPP thresholds for all 
patients. The most frequently utilised practice guidelines amalgamating this evidence are those 
published by the Brain Trauma Foundation;30 which recognises the limited evidence available, and 
suggests a CPP range between 50-70mmHg, to balance between the risks of cerebral ischaemia and 
the cardiorespiratory complications of induced hypertension. The idea that CPP thresholds may vary 
between individuals is mentioned, but there is no suggestion as to how this might be applied to 
clinical practice.  
The strengths of this review are that we followed best-practice in systematic review methods,14 
including a rigorous search of published and unpublished material, and two authors extracted and 
appraised the data.  One notable source of potential bias in the review process is that the majority of 
the studies were published by the Cambridge group who devised, and have a financial interest in, 
the ICM+ software.  Those studies performed entirely independently of any members of the 
Cambridge cohort,23,26,27 and those using alternative techniques23,26  reported similar results to the 
Cambridge group, which is encouraging against bias, but this potential conflict of interest should be 
borne in mind by the readership.  Additionally, the inclusion of the authors of the Cambridge cohort 
studies in our review team might introduce bias, however they were not involved in the risk of bias, 
data synthesis or GRADE ratings of this review.  
The published data suggest a positive association between proximity of CPP to CPPopt and clinical 
outcome, although the poor quality of the evidence prevents firm conclusions from being drawn. 
Evolving methods are allowing for CPPopt recommendations to be made by applying relatively 
simple software to data which are routinely gathered, providing the potential for a very cost-
effective intervention to be used by even small centres (one could foresee online-access for 
occasional users). An increasing number of neurocritical care units are adopting the technology, and 
current data lends some support towards its use. 
There is not currently enough high quality evidence to make recommendations for implementing a 
CPPopt-based strategy over the usual CPP targets suggested by the Brain Trauma Foundation. To 
truly identify the impact of a CPPopt-based strategy, well designed prospective randomised-
controlled trials comparing the standard CPP recommendations to CPPopt targeting must be 
undertaken. These should address clinically meaningful outcomes such as mortality, Glasgow 
Outcome Scale and neuropsychological measures, and should include rigorous reporting of 
confounding factors such as baseline severity, additional injuries and complications during 
admission. Recommendations for improving the quality of TBI trials have been published as part of 
the IMPACT Project.31 
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Table 1: Summary of Study Characteristics 
 
 
CPPopt = Optimal cerebral perfusion pressure, DATCAR (LAx) = dynamic adaptive target of active cerebral 
autoregulation (low-resolution autoregulation index), GOS = Glasgow Outcome Scale, ICM+ PRx = 
cerebrovascular pressure reactivity index calculated by ICM+ software, NOS = Not otherwise specified, NR = 
Not recorded, Retro. Ax  of prosp,data = Retrospective analysis of prospectively collected data  
 
Table 2: Summary of Risk of Bias 
U = Unclear 
 
Study Years Studied 
(Setting) 
Design N = Age 
(Years) 
TBI Severity CPPopt Method Outcomes 
(Time, months) 
Cambridge Cohort 
 
Aries (2012)22 
Lang  (2014)25 
Smielewski (2012)24 
2003-2011 (UK) 
 
2003-2009 
2003-2009  
2003-2011  
Retro. Ax  of prosp,data 
 
   
 
 
327 
307 
400 
 
 
38 
36  
NR 
Severe  
 
ICM+ PRx  
ICM+ PRx; L-PRx  
ICM+ PRx 
GOS (6) 
Colton (2014)26 2008-2010 
(US) 
Retro. Ax  of prosp,data 138 40 NR Low frequency 
PRx 
Functional 
Outcome NOS  (6) 
Depreitere (2014)23 2003-2005 
(Belgium) 
Retro. Ax  of prosp,data 264 33 NR ICM+ PRx 
DATCAR (LAx) 
Survival (6) 
Dias  
(2015)29 
2011-2013 
(Portugal) 
Prospective cohort study 18 42 Severe ICM+ PRx GOS (6) 
Jaeger (2010)27 2005-2007 
(Germany) 
Prospective cohort study 38 40 Mild-Severe ICM+ PRx PbrO2 
Steiner (2002)28 1997-2000 
(UK) 
Retro. Ax  of prosp,data 114 34 Mild-Severe ICM+ PRx GOS (6) 
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Cambridge 
Cohort 
 
Aries (2012)22  
Lang (2014)25 
Smielewski 
(2012)24 
Low 
 
 
Low  
Low 
U 
Low 
 
 
Low  
Low 
U 
Low 
 
 
Low 
Low 
U 
Low 
 
 
Low 
Low 
U 
High 
 
 
High 
High 
U 
Low 
 
 
Low 
Low 
U 
Low 
 
 
Low 
Low 
U 
Low 
 
 
Low 
Low 
U 
High 
 
 
High 
High 
U 
Low 
 
 
Low 
Low 
U 
Low 
 
 
Low 
Low 
U 
Low 
 
 
Low 
Low 
U 
Colton 
(2014)26 
U U U U U U U U U U U U 
Depreitere 
(2014)23 
Low Low Low Low Low Low Low Low Low Low Low Low 
Dias  
(2015)29 
Low Low Low Low High High Low Low High Low Low Low 
Jaeger 
(2010)27 
Low Low Low Low Low Low Low Low Low Low Low Low 
Steiner 
(2002)28 
Low Low Low Low High Low Low Low High Low Low Low 
  
 
Table 3: Summary of Main Outcomes 
 
Study Mortality Neurological Outcome Physiological Outcome 
Cambridge 
Cohort22,24,25 
RR 0.28 (p = 0.015) if (ΔCPP-
CPPopt) <5mmHg  
 
More likely if CPP<CPPopt (No 
effect size reported; p<0.001) 
GOS 4-5 more likely if (ΔCPP-CPPopt) <5mmHg (RR 
1.65; p <0.001)  
 
Severe disability (GOS 3) more likely if CPP 
>5mmHg above CPPopt (RR 1.88 p<0.001).   
 
Severe disability (GOS 3) more likely if CPP>CPPopt 
(p=0.005; No effect size reported) 
 
CPP > CPPopt correlated with greater rate of 
severe disability (p<0.025; No effect size reported). 
 
Colton (2014)26 
 
RR 0.42 if (ΔCPP-CPPopt) <5mmHg 
vs (ΔCPP-CPPopt) >10mmHg (no P-
value reported) 
 
Poor outcome (NOS) more likely if (ΔCPP-CPPopt) 
>10mmHg vs <5mmHg (RR 2.14; no P-value 
reported) 
 
Depreitere 
(2014)23 
Proportion of time spent within 
5mmHg of CPPopt higher for 
survivors than non-survivors 
(25.6% vs 19.6% p=0.01).  
 
  
  
CPP = cerebral perfusion pressure, CPPopt = optimal cerebral perfusion pressure, ΔCPP-CPPopt = 
difference between actual CPP and CPPopt,, GOS = Glasgow Outcome Sale, NOS = Not otherwise 
specified, PbrO2 = partial pressure of brain tissue oxygen, RR = relative risk 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(ΔCPP-CPPopt) = independent 
negative predictor of survival 
(p=0.017; No effect size reported) 
Dias (2015)29  CPP<CPPopt lower in those with GOS <3  
(-6.6mmHG vs -1.0mmHg; p=0.04)  
 
Jaeger (2010)27   CPP and PbrO2 correlate up 
to, but not higher than, 
CPPopt (r=0.51; p<0.001) 
Steiner (2002)28 RR 0.17 if CPP > CPPopt  (no P-
value reported) 
 
(ΔCPP-CPPopt) correlates with GOS (r= -0.51; 
p<0.001), both when CPP<CPPopt (r=0.53; 
p<0.001) and when CPP>CPPopt (r=-0.40; p=<0.05) 
 
Records identified through 
database searching 
(n = 13424) 
Sc
re
en
in
g 
El
ig
ib
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ty
 
Id
en
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n 
Additional records identified 
through other sources 
(n =  0) 
Records after duplicates removed 
(n = 2020) 
Records screened 
(n = 74) 
Full-text articles assessed 
for eligibility 
(n = 22) 
Full-text articles excluded  
(n = 14) 
8 Did not calculate CPPopt 
2 Were abstracts of 
Records excluded  
(n = 1946) 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Flow Diagram of Study Selection Process. CPPopt = Optimal cerebral perfusion pressure 
 
 
 
 
GRADE criteria Rating  Footnotes (reasons for downgrading) 
Quality of 
the evidence  
Neurological Outcome 
Risk of Bias Serious (-1)   
Supplementary Table 1. Quality of Evidence (GRADE) 
 
 
 
 
 
 
PbO2: Brain tissue oxygen partial pressure 
 
 
Supplementary Table 2: Summary of Excluded Studies 
Confounders poorly controlled for 
across most studies 
Very Low 
 
 Inconsistency No Effect direction and sizes similar 
Indirectness Serious (-1) No comparison with usual management 
Imprecision Not assessable 
 
Number of events and confidence 
intervals not presented. 
Publication Bias Undetected  
Other No upgrading factors  
GRADE criteria R ting  Footnotes (reasons for downgrading) 
Quality of 
the evidence  
Mortality 
Risk of Bias Serious (-1) 
 
Confounders poorly controlled for 
across most studies 
 
Very Low 
Inconsistency No Effect direction and sizes similar 
Indirectness Serious (-1) No comparison with usual management 
Imprecision Not assessable 
 
Number of events and confidence 
intervals not presented. 
Publication Bias Undetected  
Other No RR <0.5 in at least 2 studies, but plausible confounders present 
GRADE criteria Rating  Footnotes (reasons for downgrading) 
Quality of 
the evidence  
PbO2 
Risk of Bias No Single study at low risk of bias  
Very Low Inconsistency No Only one study 
Indirectness Serious (-1) Surrogate outcome for clinical relevance 
Imprecision Serious (-1) Highly significant result but very small number of participants  
Publication Bias Undetected  
Other No upgrading factors  
CPPopt = Optimal cerebral perfusion pressure 
 
 
 
 
 
 
Appendix 1: Summary of CPPopt Techniques 
 
The cerebrovascular pressure reactivity index (PRx) is a marker of cerebrovascular autoregulation 
derived from the response of intracranial pressure (ICP) to slow fluctuations in arterial blood 
pressure (ABP). All the described CPPopt calculations below are based on this index. 
 
ICM+ PRx: 
Digitized signals from ICP and ABP monitors are sampled at a frequency of 100 Hz, and recorded 
using ICM+ software.  Time-averaged values of ICP, ABP, and CPP are calculated using waveform 
time integration over 60-sec intervals. A moving Pearson correlation coefficient is calculated 
between 30 consecutive, 10-sec averaged values of ABP and corresponding ICP signals (with 80% 
overlap of data ) to provide a measure of cerebrovascular PRx.  The influence of the pulse- and 
respiratory-frequency wave components is supressed by the averaging over 10 seconds.  A U-shaped 
curve is fitted to the PRx values over the range of CPP seen in the preceding 4 hours, with the lowest 
PRx value indexing current value of CPPopt. If certainty of U-shape curve fit is low, CPPopt value is 
Study Reason for Exclusion 
Aries 201420 Data presented as full-text in other included 
article 
Guiza 201321 Data presented as full-text in other included 
article 
Nordstrom 200532 No data presented 
Ang 200733 CPPopt not calculated 
Zweifel 200834 No new data; quotes data from Steiner et al. 
2002 
Brady 200935 CPPopt not calculated 
Consonni 200936 CPPopt not calculated 
Radolovich 201137 CPPopt not calculated 
Aries 201238 CPPopt not correlated with outcome measure 
Budhohoski 201239 CPPopt not calculated 
Smielewski 201240 CPPopt not correlated with outcome measure 
Sorrentino 201241 CPPopt not calculated 
Johnson 201442 CPPopt not calculated 
Lazaridis 201443 CPPopt not calculated 
automatically discarded. This routine is repeated every minute and CPPopt may be presented as a 
monitored variable, compared to real CPP trend.  
 
Long-PRx: 
The Long-PRx relies on the same method as ICM+ PRx, but is calculated as a moving Pearson 
correlation coefficient between 20 data points of ICP and ABP averaged over a 60 second period, as 
opposed to 30 data points averaged over a 10 second period in PRx. There are no particular 
advantages suggested over the standard PRx method, simply an alternative measure. 
 
Dynamic adaptive target of active cerebral autoregulation (DATCAR; LAx): 
The low-resolution autoregulation index (LAx) is calculated as the correlation coefficient between 
minute-by-minute measurements of ICP and ABP for 8 separate time intervals 3, 5, 10, 20, 30, 60, 
90, and 120 minutes. 
 
CPPopt is calculated as in ICM+ PRx, fitting a U-shaped curve with the most negative values of the 
autoregulation index indicating optimal CPP. Instead of limiting this to the previous 4 hours of data 
however, the method is applied on time windows of 1, 2, 4, 6, 8, 12, and 24 hours, for each LAx time 
interval defined above. Therefore, 45 plots are generated for each point in time. These plots are 
then weighted based on 2 criteria: the better the fit of the U-shaped curve, and the lower the LAx-
value corresponding to the plot-specific CPPopt. The final CPPopt is thus computed as the weighted 
average of the CPPopts. This method of calculating CPPopt aims to optimize the ability to detect 
periods of active autoregulation in the preceding period, thereby being more likely to generate a 
mathematically reliable CPPopt. 
 
